Altered Salivary Microbiota Following *Bifidobacterium animalis* Subsp. *Lactis* BL-11 Supplementation Are Associated with Anthropometric Growth and Social Behavior Severity in Individuals with Prader-Willi Syndrome

Kevin Liu1 · Xue-Jun Kong1,2

Accepted: 4 April 2022 / Published online: 26 April 2022 © The Author(s) 2022

Abstract

To evaluate the influence of oral probiotic *Bifidobacterium animalis* subsp. *lactis* (BL-11) supplementation on salivary microbiota composition and the association with growth parameters, and behavioral symptoms in individuals with Prader-Willi syndrome (PWS). In this post hoc analysis, we included a subset of 36 PWS patients with available saliva samples from our original randomized, double-blinded, placebo-controlled trial (Chinese Clinical Trial Registry, ChiCTR1900022646, April 20, 2019). Among the 36 subjects, 17 subjects were allocated to the probiotic group for daily use of the BL-11 probiotic and 19 subjects were allocated to the placebo group. Groupwise and longitudinal differences in salivary microbiota abundances, biodiversity metrics, and height were analyzed. Linear correlations were found between identified differentially abundant salivary microbiota and clinical parameters. Salivary microbiome α-diversity was found to be higher in the probiotic-treated group at week 12 relative to placebo controls (*P* < 0.05). *Lepotrichia*, *Paracoccus*, and *Faecalibacterium* were found to be more abundant in the probiotic-treated group (*P* < 0.05). Salivary microbiota abundance and predicted functional profiling abundance correlations were found to be associated with anti-inflammation, anti-obesity, toxin degradation, and anti-oxidative injury effects (*Q* < 0.1). Several oral taxa also displayed correlations with social behavior severity scores in the probiotic-treated group (*Q* < 0.1). The findings suggest novel salivary microbiota compositional changes in response to the oral supplementation of BL-11 probiotic in individuals with PWS. The observed differentially abundant taxa between groups post-treatment were highly correlated with interventional effects on growth and social behaviors, although further investigation is warranted. Clinical Trial Registration The original clinical trial was registered under the Chinese Clinical Trial Registry with registration number ChiCTR1900022646 (April 20, 2019).

Keywords Prader-Willi syndrome · Saliva · Microbiome · Probiotics · *Bifidobacterium* · Height

Introduction

Prader-Willi syndrome (PWS) is a rare genetic disorder featuring severe hypotonia and feeding difficulties in early infancy and subsequent hyperphagia and early childhood onset obesity. Additionally, developmental delay, short stature, and numerous neuropsychiatric comorbidities have been implicated in individuals with PWS and it has been recognized as a type of syndromic autism spectrum disorder (ASD) [1–4]. Given the diverse array of symptoms associated with PWS and an increasing popularity in multi-omics research, there is a growing body of literature supporting linkages between alterations in the gut microbiota and the clinical manifestations of PWS-associated features; however, few studies have attempted to characterize the salivary microbiome composition and elucidate the potential interactions with the gut microbiome. Specifically, while past studies have shown that dysbiotic gut microbiota of individuals with PWS have been implicated in the etiology of obese PWS patients and associated worsening of insulin tolerance.
[5, 6], the host-salivary microbiota interactions and potential salivary microbiome dysbiosis in PWS patients have yet to be explored despite evidence found within individuals with ASD [7, 8]. As several past studies have shown improvements in metabolic disturbances and gut microbiome dysbiosis in both obese mice and overweight human adults following probiotic supplementation [9, 10], we recently published clinical trials of probiotic supplementation for the treatment of anthropometric growth-associated comorbidities in PWS [11, 12]. In our study on Bifidobacterium animalis subsp. lactis (BL-11) supplementation in individuals with PWS, we found a significant increase in height and improvement in behavioral symptoms following probiotic treatment and both the gut microbiota composition and metagenomic functional profiles also favored effects of weight loss and gut health with increased abundances of antioxidant production-related genes [12]. While such linkages have been established between changes in gut microbiota and the developmental features of PWS in our past studies, associated changes in the oral microbiome have yet to be elucidated despite the known interactions between the salivary and gut microbiomes in ASD [13]; thus, we hypothesize that probiotics targeted at modulating the gut microbiota may also display altered patterns of oral flora.

In contrast to the well-studied gut microbiome, characterization of salivary microbiota composition and biodiversity have not yet been explored in PWS populations despite that the oral microbiome has been recognized as potential key biomarkers of several oral and systemic diseases that may be related to symptoms of PWS [14]. For example, PWS patients were found to have high rate of oral diseases such as caries and tooth wear due to developmental delay, hyperphagia, and thick saliva [15]. As the human salivary microbiota is comprised of highly diverse groups of commensal, symbiotic, and pathogenic microorganisms, current research has suggested that such influences of the salivary microbiota extend beyond that of the oral cavity [16]. For instance, existing literature have shown that oral microbiota possesses the ability to translocate to the gut with the potential to modulate the gut microbiome, host immune defense, and brain function [17, 18]. Since our probiotic is supplied in a powder-containing sachet format, we believe that the BL-11 probiotic supplementation has the ability to influence the oral microbiota in addition to modulating the gut microbiome given that the active probiotic powder passes through the oral cavity.

With our current understanding of the multidimensional interactions of salivary microbiota with gut microbiota, immune function, and brain function, it is of interest to study such associations within the context of individuals with PWS. However, these areas of interests regarding the salivary microbiome, its relationship with core symptoms of PWS and gut microbiome composition, effects of longitudinal probiotic supplementation, and subsequent changes in the salivary microbiota in individuals with PWS have not been previously explored. To fill these gaps of knowledge on the salivary microbiota in PWS, we performed the present post hoc analysis based on our recently published clinical trial [12] to characterize the oral microbiome profile in PWS patients, examine its changes following BL-11 probiotic intervention, and assess its associations with height growth, social behavior symptom severity, and the relative levels of metagenomic functional pathways.

**Materials and Methods**

**Study Design**

The original clinical trial design, protocol, randomization, blinding, participant eligibility, and intervention were well described in our previous publications [11, 12]. The original clinical trial was registered under the Chinese Clinical Trial Registry with registration number ChiCTR1900022646 (April 20, 2019) and involved 65 PWS subjects that were double-blinded and randomly assigned to either the probiotic interventional group or the placebo control group [12]. The enrolled subjects were subject to treatment for a total duration of 12 weeks. In this post hoc analysis study, we included a subset of 36 subjects with ages 59.49 ± 40.56 months who had available salivary sample 16 s sequencing data. Among the subset of 36 subjects, 17 subjects (aged 60.66 ± 32.19 months) were allocated to the probiotic group and 19 subjects (aged 58.5 ± 47.34 months) were allocated to the placebo group. The probiotic Bifidobacterium Animalis subsp. lactis BL-11 (Beijing Huayuan Academy of Biotechnology) was used in the study in the format of a sachet containing the probiotic BL-11 in powder form. Each sachet of probiotics supplement contained 3 x 10^10 colony forming units (CFUs). The placebo was maltodextrin in the sachet with similar color, flavor, and taste as the probiotic sachets. Subjects received one sachet twice a day of either probiotic or placebo for a duration of 12 weeks and were instructed to consume the sachet contents orally with water. No adverse events were observed throughout the study course. An illustration of the timeline, sample sizes, and participant drop-outs is shown in Fig. 1.

**Outcome Measurements and Data Collection**

Outcome measurements were taken at weeks 0 (baseline), 6, and 12. Weight and height measurements were measured by parents using standard scales and recorded by the research staff for all enrolled subjects regardless of age. Restricted/repetitive behaviors (RRB), social interaction (SI), social...
communication (SC), emotional response (ER), cognitive style (CS), and maladaptive speech (MS) were evaluated by an experienced clinician via the Gilliam Autism Rating Scale, Third Edition (GARS-3), for those of ages 3 years or older [19]. Furthermore, medical, dental, and dietary histories were recorded during the visits.

**DNA Extraction and 16S Ribosomal RNA Amplicon Sequencing of Saliva Samples**

Bacterial genomic DNA was extracted from saliva samples using the Powersoil DNA isolation kit (Qiagen, Duesseldorf, Hilden, Germany) with the bead-beating method according to the manufacturer’s instructions. Characterization of the salivary microbiota was done via high fidelity 16S rRNA amplicon gene sequencing based on collected saliva samples of all subjects of this study.

**Bioinformatics Processing of Amplicon Sequencing Data**

Sequencing reads were bioinformatically processed using Biobakery Workflows (v0.13.2) [20] based on the VSEARCH (v2.14.1) [21] method. In short, the sequences were demultiplexed and VSEARCH was used with default parameters to merge, filter, and trim the Illumina data. The sequences were then dereplicated, sorted by size, and clustered into operational taxonomic units (OTUs). Next, phylogenetic trees were constructed using FastTree [22] after alignment of sequences using Clustal Omega [23]. The taxonomies of OTUs were assigned using the Greengenes database (v13.8) with sequences sharing 97% similarity [24]. Both R and the R package phyloseq [25] were used to perform downstream metagenomic processing, including agglomeration of OTUs at the genus level, transformation of reads to relative abundances, OTU filtering using a prevalence threshold of 0.0001 and an occurrence threshold of 10% of the population, and calculation of α-diversity indices. For creating co-abundance networks via MetagenoNets [26], reads were transformed via total sum scaling and filtered using a prevalence threshold of 0.0001 and an occurrence threshold of 10% of the population.

**Statistical Analysis**

All raw data were recorded and processed in Microsoft Excel 2016 and R. Statistical procedures were carried out using $\alpha = 0.05$ as the significance level and $Q < 0.1$ for adjusted $P$-values. Data analysis and visualization were performed under R using the tidyverse package while statistics were generated using the compatible ggpubr and rstatix package. Linear mixed effects models and associated analysis were performed using the lme4 and emmeans packages.

Linear mixed effects models with maximum likelihood estimation were used to test the impact of BL-11 probiotic supplementation on the course of outcomes from the three study timepoints (weeks 0, 6, and 12) compared to receiving the placebo. In the models, treatment group (probiotic and placebo groups), study timepoint (weeks 0, 6, and 12), and the interaction between treatment group and timepoint were set as fixed effects. Participants were included as random effects. The effect of BL-11 probiotic supplementation was estimated based on the interaction between treatment group and timepoint. Furthermore, the post hoc interaction contrasts between treatment group and timepoint were determined.

Differential abundance analysis at the genus level was conducted using linear discriminant analysis (LDA) effect
size (LEfSe) [27] by applying an LDA score minimum threshold of 2 and a significance cutoff of $\alpha = 0.05$ for groupwise comparisons. Univariate linear correlations via MaAsLin2 [28] were used to explore per-feature correlations between clinical indices, including GARS-3 total and subscale scores, weight, height, and BMI, predicted functional profiling features, and genus-level OTU abundances; the resulting $P$-values were adjusted for multiple testing using false-discovery rate (FDR). Genus-level salivary microbiota co-abundance network analyses were processed, analyzed, and plotted in MetagenoNets [26] using the NAMAP with Spearman’s rank correlation algorithm while applying a significance cutoff of $\alpha = 0.05$ with 100 bootstrap iterations.

**Results**

**Summary of Baseline Subject Demographics and Clinical Indices**

We included 36 subjects aged 59.49 ± 40.56 months (52.78% male, 47.22% female) with genetically confirmed diagnosis of PWS. Of which, 17 subjects aged 60.66 ± 32.19 months were randomized to receive the active probiotic, while 19 subjects aged 58.5 ± 47.34 months were randomized to receive placebo for a duration of 12 weeks. Among the 36 subjects included in this study, there were 29 of them had available GARS-3 dataset (GARS-3 is only applicable for those age 3 or above), 17 subjects were in placebo group, and 12 subjects were in probiotics group. No adverse events were reported during the trial period. A summary of the subject demographics and detailed clinical indices are provided in Table 1, which indicated no significant differences between the probiotic and placebo groups among all the demographic and clinical parameters as listed. We analyzed and observed a trend of increasing height over time in those receiving the probiotic treatment, but not in those receiving the placebo (Fig. 2). We performed a linear mixed effects model analysis to determine the effects of treatment groups over the three study timepoints for height. The estimated marginal means (EMM), their standard errors (SE), and the contrasts between the three study timepoints for height are detailed in Table 2, accompanied by the differences in the contrasts between the treatment groups and timepoints. Of note, the comparisons using a series of contrasts have shown significant differences for the differences in height in the probiotic group between weeks 12 and 0 and weeks 6 and 0 (Table 2, $P < 0.001$).

**Salivary Microbiome Biodiversity and Co-abundance Network Changes Following BL-11 Supplementation**

Changes in the salivary microbiome biodiversity were assessed through groupwise comparisons at each study timepoint via Mann–Whitney $U$ tests for $\alpha$-diversity indices at weeks 0, 6, and 12 (Online Resource 1). An increasing trend in Shannon index, Simpson index, and Inverse Simpson index was observed over the 12-week study.

| Table 1 | Summary of baseline subject demographics and measured clinical indices |
|---------|-------------------------------------------------|
|         | Placebo ($n = 19$) | Probiotic ($n = 17$) | $\chi^2$-test $P$-value | Overall ($n = 36$) |
| Sex ($n$) | | | | |
| Male | 10 (52.63%) | 9 (52.94%) | 0.99 | 19 (52.78%) |
| Female | 9 (47.37%) | 8 (47.06%) | 17 (47.22%) |
| Mean (SD) Median (IQR) | Mean (SD) Median (IQR) | Mann–Whitney $U$ test $P$-value | Mean (SD) Median (IQR) |
| Age (month) | 58.5 (47.34) 40.5 (53) | 60.66 (32.19) 58.5 (43.38) | 0.48 | 59.49 (40.56) 46.5 (48.25) |
| Height (cm) | 111.25 (20.71) 112.5 (33.25) | 107.4 (21.37) 112 (33) | 0.81 | 109.11 (19.83) 112 (37) |
| Weight (kg) | 26.45 (15.29) 26.65 (25.35) | 29.8 (20.02) 29 (24) | 0.90 | 28.31 (17.06) 29 (24.8) |
| Body mass index (BMI) | 19.47 (5.04) 19.55 (8.49) | 23.01 (9.07) 18.86 (13.39) | 0.73 | 21.43 (7.36) 18.86 (8.55) |
| GARS-3 $n = 17$ | 10 (3.5) 11 (2) | 8.67 (2.08) 8.2 (2) | 0.82 | 9.33 (2.73) 9.5 (3.75) |
| Cognitive style (CS) | 10.33 (3.21) 9 (3) | 15.33 (4.04) 13 (3.5) | 0.38 | 12.83 (4.26) 13 (3.75) |
| Emotional responses (ER) | 10 (5.29) 12 (5) | 7.33 (3.79) 9 (3.5) | 0.40 | 8.67 (4.37) 9.5 (6.25) |
| Maladaptive speech (MS) | 19 (6) 19 (6) | 24.33 (9.29) 20 (8.5) | 0.70 | 21.67 (7.58) 19.5 (5.5) |
| Restricted/Repetitive behaviors (RRB) | 19.33 (6.81) 17 (6.5) | 12.33 (7.57) 9 (7) | 0.40 | 15.83 (7.49) 15.5 (9.75) |
| Social communication (SC) | 10.67 (2.52) 11 (2.5) | 9.33 (8.02) 10 (8) | 1.00 | 10 (5.37) 10.5 (4) |
| Social interaction (SI) | 10.67 (2.52) 11 (2.5) | 9.33 (8.02) 10 (8) | 1.00 | 10 (5.37) 10.5 (4) |
period between groups and a significant groupwise difference is observed at week 12 (Fig. 3A, Mann–Whitney U test, \( P < 0.05 \)). Bray–Curtis \( \beta \)-diversity was plotted using principal coordinates analysis (PCoA, Fig. 3B) and showed statistically significant differences between the four sample groups, including placebo-stool, placebo-saliva, probiotic-stool, and probiotic-saliva groups (\( F = 51.334, R^2 = 0.56827, P = 0.001 \)).

To characterize the interactions between genus-level salivary microbiota through their respective abundances by group per each study timepoint, we constructed co-abundance networks based on the NAMAP with Spearman’s rank correlation algorithm as shown in Fig. 4A. An overview of the number of unique and shared edges within each group based on the treatment status is shown in Fig. 4B.

### Differentially Abundant Genus-Level Salivary Microbiota Following BL-11 Supplementation

The salivary microbiota abundance changes over the course of probiotic supplementation were assessed through both groupwise comparisons of genus-level microbiota relative abundances for specific genera of interest, including the *Bifidobacterium* genus, and via LEfSe for comparison of overall genus-level microbiota abundance changes post-treatment (i.e., samples from 6 to 12 weeks combined). The *Bifidobacterium* genus relative abundance displayed an increasing trend over the treatment course in the active probiotic group and showed significant groupwise differences in relative abundance at week 12 (Fig. 5A, Mann–Whitney U test, \( P < 0.05 \)).

---

**Table 2** Summary of estimated marginal means and computed contrasts for linear mixed effects model analysis using timepoint and group interaction as fixed effects and subjects as random effects

| Group     | Timepoint (weeks) | Contrast               | EMM (SE)       | 95% CI             | df  | t-ratio | P-value |
|-----------|-------------------|------------------------|----------------|--------------------|-----|---------|---------|
| Probiotic | 12                | Probiotic 12–placebo 12| 3.37 (7.51)    | (−21.11, 27.86)    | 37.31 | 0.449   | 0.838   |
|           |                   | Probiotic 12–placebo 6 | 1.43 (0.59)    | (−0.5, 3.35)       | 35.61 | 2.424   | 0.077   |
|           |                   | Probiotic 12–placebo 6 | 4.65 (7.52)    | (−19.85, 29.15)    | 37.40 | 0.619   | 0.838   |
|           |                   | Probiotic 12–placebo 0 | 6.67 (0.95)    | (3.56, 9.77)       | 35.71 | 7.021   | <0.001  |
|           |                   | Probiotic 12–placebo 0 | 6.34 (7.57)    | (−18.28, 30.96)    | 38.35 | 0.837   | 0.838   |
| Placebo   | 12                | Placebo 12–placebo 6   | −1.94 (7.51)   | (−26.43, 22.54)    | 37.34 | −0.259  | 0.854   |
|           |                   | Placebo 12–placebo 6   | 1.28 (0.59)    | (−0.65, 3.21)      | 35.64 | 2.167   | 0.111   |
|           |                   | Placebo 12–placebo 0   | 3.29 (7.54)    | (−21.28, 27.72)    | 37.93 | 0.436   | 0.838   |
|           |                   | Placebo 12–placebo 0   | 2.97 (1.14)    | (−0.75, 6.68)      | 35.79 | 2.608   | 0.066   |
|           |                   | Placebo 12–placebo 0   | 10.05 (5.08)   | (88.5, 121.61)     | 37.31 |         |         |
| Probiotic | 6                 | Probiotic 6–placebo 6  | 3.22 (7.52)    | (−21.28, 27.72)    | 37.43 | 0.429   | 0.838   |
|           |                   | Probiotic 6–placebo 0  | 5.24 (0.99)    | (2.02, 8.46)       | 35.72 | 5.317   | <0.001  |
|           |                   | Probiotic 6–placebo 0  | 4.91 (7.57)    | (−19.72, 29.54)    | 38.38 | 0.649   | 0.838   |
| Placebo   | 6                 | Placebo 6–placebo 0    | 103.78 (5.09)  | (87.21, 120.35)    | 37.50 |         |         |
|           |                   | Placebo 6–placebo 0    | 2.02 (7.55)    | (−22.56, 26.59)    | 38.02 | 0.267   | 0.854   |
|           |                   | Placebo 6–placebo 0    | 1.69 (1.09)    | (−1.89, 5.27)      | 35.75 | 1.542   | 0.330   |
|           |                   | Placebo 6–placebo 0    | 101.76 (5.58)  | (83.61, 119.91)    | 38.45 |         |         |
|           |                   | Placebo 6–placebo 0    | −0.33 (7.6)    | (−25.03, 24.38)    | 38.97 | −0.043  | 0.966   |
| Placebo   | 0                 | Placebo 0–placebo 0    | 102.09 (5.16)  | (85.33, 118.85)    | 39.58 |         |         |
U test, \(W = 63, P < 0.05\). Examining all remaining genus-level OTUs following filtering by prevalence and occurrence thresholds, the Leptotrichia (LDA score = 4.170, \(P < 0.05\)), Paracoccus (LDA score = 2.553, \(P < 0.05\)), and Faecalibacterium (LDA score = 2.473, \(P < 0.05\)) genera were significantly more abundant in the probiotic group salivary microbiome, whereas the Victoria genus (Mitochondria) was significantly more abundant in those receiving placebo (LDA score = 3.073, \(P < 0.05\), Fig. 5B). Among the three identified differentially abundant genera determined via LEfSe in the probiotic group, Paracoccus relative abundance was found to be negatively correlated with GARS-3 cognitive style (CS) score (Fig. 5C, Kendall rank correlation, \(R = -0.036, P < 0.05\)) while other differentially abundant microbiota were not found to be significantly correlated with social behavior severity scores.

**Fig. 3** Overview of salivary and fecal microbiome biodiversity measures. a Genus-level \(\alpha\)-diversity via Shannon index, Simpson index, and Inverse Simpson index at week 12 for the salivary microbiome. Groupwise comparison were conducted via Wilcoxon rank-sum test. b PCoA of filtered fecal and salivary genera using Bray–Curtis dissimilarity \(\beta\)-diversity post-treatment (i.e., weeks 6 and 12 combined). The PCoA plot explained 59.96% of the variance and 95% confidence ellipses are shown. Differences in sample groups were assessed via PERMANOVA and relevant statistics are reported above the plot.

**Associations Between Post-Treatment Social Behavior Severity, Height, Weight, Predicted Functional Pathways, and Salivary Microbiota Abundance**

In an attempt to elucidate the functional role of differentially abundant microbiota and determine the relationships between salivary microbiota relative abundance, social behavior symptom severity, weight, and height following active probiotic supplementation, we performed univariate linear regression with FDR adjustments for genus-level microbiota correlations against height, weight, and GARS-3 total and subscale scores. Similarly, functional metagenomic profiles were correlated against the three differentially abundant microbiota identified with higher abundance in the probiotic group, including Leptotrichia, Paracoccus, and Faecalibacterium to explore the
potential microbial functions associated with each genus. Statistical significance was considered by applying a significance cutoff of FDR < 0.1 and the resulting correlations are presented in the figures presented in Online Resources 2 and 3.

**Discussion**

In the present post hoc study, we explored the salivary microbiota differences before and after supplementation with the probiotic *Bifidobacterium animalis* subsp. *lactis*. 

---

**Fig. 4** Genus-level salivary microbiota co-abundance networks by group per each study visit via the NAMAP with Spearman’s rank correlation algorithm. a Salivary co-abundance networks were visualized at weeks 0 (baseline, all subjects), 6, and 12 for each group. Nodes (circles) are sized and ordered concentrically by degree (i.e., number of connected edges). Edges (lines) are colored by the directionality of the correlation between two features. b Venn diagram of salivary taxa edges shared between groups and treatment status. Numbers in bold show the number of identified edges within the specified group and study timepoint.
BL-11 in individuals with PWS and assessed their associations with predicted functional profiles, behavioral severity scores, and anthropometric growth measures. Despite having a smaller sample size in this study (N=36) compared to the original trial (N=65) due to missing saliva 16 s rRNA amplicon sequencing samples, we were able to retain groupwise symmetry in age, height, weight, and behavioral severity parameters at baseline. Furthermore, we were able to confirm the trend of height increase with statistical significance found between weeks 12 and 0 as well as between weeks 6 and 0 in the probiotic group, which are consistent with our findings in the original trial [12]. Performed as a result of the smaller sample size in the present study, the results of these confirmatory analyses further validated our current study population as representative of the original trial.

In contrast to the well-reported gut microbiota changes with probiotic supplementation in individuals with PWS, salivary microbiota changes following probiotic intervention have not been previously reported. In this study, we found that α-diversity in terms of Shannon index, Simpson index, and Inverse Simpson index exhibits an increasing trend over the treatment course for those receiving the BL-11 probiotic and is significantly higher relative to the placebo controls at week 12. The PCoA of Bray–Curtis dissimilarity β-diversity shows defined, separated clusters between salivary and fecal microbiome clusters regardless of the treatment group (i.e., receiving either BL-11 or placebo), which is suggestive of inter-microbiome differences in biodiversity and is consistent with our expectations. Namely, we attribute the statistical significance found between the four sample groups to the compositional differences between groups following treatment (6 and 12 weeks combined).
PWS individuals’ salivary and fecal microbiomes as the distinct separation between the salivary and stool clusters are separated by axis 1, which explained 52.5% of the variance among participants, rather than axis 2 that only explained 7.46% of the variance. Of note, the evaluation of the β-diversity differences for the salivary microbiome is likely limited by the smaller sample size relative to the fecal microbiome. As opposed to our previous findings in the gut microbiome β-diversity between treatment groups [12], the results regarding the salivary microbiome biodiversity from the present study suggests that while oral supplementation of BL-11 does not alter the β-diversity between treatment groups, subjects receiving the BL-11 probiotic independently exhibit more heterogeneity in the salivary flora as shown through the higher α-diversity at week 12. To further characterize the interactions between salivary microbiota of those receiving the BL-11 probiotic relative to those receiving the placebo, we constructed genus level co-abundance networks and observed higher numbers of edges in the post-BL-11 treatment group at week 12. The larger number of edges (i.e., significant correlations) at week 12 between microbiota abundances of the probiotic group exhibits a 1.6-fold increase over that of the placebo group and 139 edges are uniquely found within the probiotic group at week 12, which suggests that introduction of the BL-11 probiotic to the oral cavity has significantly enhanced the interactions between salivary microbiota in addition to the induction of an increase in salivary microbiome α-diversity; however, the physiological implications regarding an increase in genus-level co-abundance network edges post-probiotic treatment remain largely unknown and warrant further investigation. Nonetheless, we attempt to explain the changes in the salivary microbiota composition and its host interactions through specific identified differentially abundant genera. Probing for differentially abundant microbiota following probiotic supplementation, we first analyzed the genus *Bifidobacterium* to confirm that its supplementation can be detected as an increase in the overall genus-level relative abundance. We observed an increasing trend that shows significantly higher abundances of salivary *Bifidobacterium* following BL-11 treatment relative to those receiving the placebo. The change in salivary *Bifidobacterium* relative abundance at week 12 is consistent with expectations due to the method of probiotic delivery; as the probiotic was administered orally in a powder format, we expected that exposure to the BL-11 probiotic within the oral cavity can lead to the increase in oral *Bifidobacterium* over time. Assessing for differentially abundant salivary microbiota among all identified genera, we found that subjects receiving the BL-11 probiotic intervention have higher abundances of several bacterial genera relative to those receiving the placebo; these genera include *Faecalibacterium*, *Paracoccus*, and *Leptotrichia*, and will be further discussed in terms of relevance to host growth and behavioral severity below.

Relative to host-microbiota interactions mediated via the gut-brain axis, our current understanding of the oral-gut-brain axis remains largely unknown, though recent literature has suggested that oral bacterial species and their metabolites can affect the brain either directly through the cranial nervous system and circulating blood or indirectly through gut microbiota dysbiosis and systemic inflammation [29]. Furthermore, a growing body of literature has implicated multidirectional interactions between the host immune system, gut-brain interactions, and the influence of gut microbiota on growth hormone (GH)/insulin-like growth factor 1 (IGF-1) expression [13, 17, 30, 31]. Thus, we postulate that the associations identified between salivary microbiota, height, and behavioral severity scores in the present study are driven by the probiotic-induced compositional changes in salivary microbiota, ectopic translocation of oral microbiota to the gut, and subsequent modulation of gut microbiota to influence host growth through the GH/IGF-1 axis in individuals with PWS. In this study, we found that several salivary microbiota were significantly positively correlated with height post-BL-11 treatment, including the genera *Gemella*, *Aggregatibacter*, *Corynebacterium*, *Fusobacterium*, and *Treponema*, while such correlation were not statistically significant in those receiving the placebo. Given our current understanding, the identified height-correlated genera in the present study have been described in literature as largely non-pathogenic genera and are commonly found within the oral microbiome [14, 32, 33]. We postulate that these oral taxa may play a role in the mediation of childhood growth through ectopic transfer to the gut and subsequent interactions with gut microbiota, specifically in terms of height. In a study conducted by Vonaesch et al. the over-representation of oropharyngeal microbiota within the gut has been proposed to be associated with stunted growth in African children aged 2 to 5 years old [34]. Among the several over-represented oropharyngeal microbiota in the gut of children with stunted growth identified by Vonaesch et al. the genera *Gemella*, *Fusobacterium*, and *Aggregatibacter* were found to be positively correlated with height post-BL-11 treatment in the present study, thereby supporting our hypothesis of the oral-gut-brain axis in mediating host growth. These findings warrant further exploration of the oral-gut-brain interactions and their relationship with the phenotypes of PWS, which may facilitate the identification of new targeted therapies.

With a growing body of literature supporting the regulation of social behaviors via gut microbiota [35–37], we attempt to further assess the associations between salivary microbiota and behavioral severity in PWS under the hypothesis that alterations in oral microbiota can indirectly contribute to the modulation of behaviors via the oral-gut-brain axis. In our assessment of microbiota associations against
social behavior scores, Neisseria was found to be positively correlated with both GARS-3 cognitive style and maladaptive speech scores while Germella was found to be positively correlated with only maladaptive speech score following BL-11 supplementation. Provided that we have previously found compositional differences in both salivary and fecal microbiota between individuals with autism spectrum disorder (ASD) and healthy controls [13], recent literature has further identified associations between several mental disorders and oral microbiota dysbiosis [38], thereby supporting our hypothesis of oral-gut-brain interactions in PWS. Furthermore, among the three microbiota that are enriched among the salivary microbiota, the species of the Paracoccus genus also presents its relevance to host behavioral alterations. The Paracoccus genus has been previously identified in the skin flora of healthy individuals [39], which may implicate aberrant behavioral patterns in PWS as a potential cause of the inhabitation of such microbiota within the salivary microbiome. Interestingly, we identified a significant negative correlation between the relative abundance of a Paracoccus species and GARS-3 cognitive style score among subjects receiving the BL-11 probiotic while this trend was not found to be statistically significant among subjects receiving the placebo. We postulate that supplementation with the BL-11 probiotic induced an increase in the abundance of Paracoccus identified within the salivary microbiota, which could drive the release of oxytocin (OT) or other neurotransmitters through the proposed oral-gut-brain axis, similar to the previously reported effects of Limosilactobacillus reuteri probiotic-induced OT and GH release [40, 41]. OT is a well-known critical in modulating emotional and social communication [42]. Additionally, we found that the Paracoccus species were positively correlated with caffeine metabolism in those receiving the BL-11 probiotic. Caffeine was found to help fat utilization and reduction of obesity [43, 44], which is another hallmark feature of PWS. Taken together, the associations between the relative abundance of Paracoccus genus against behavioral severity scores and caffeine metabolism may implicate the salivary Paracoccus genus as a biomarker for the presence of social behavior deficits, co-morbid ASD symptoms, and probiotic treatment response if confirmed by future large-scale studies.

Among the three genera found to be enriched in PWS subjects receiving the probiotic treatment, both Faecalibacterium and Leptotrichia present relevance to host immunity and inflammatory responses. Faecalibacterium prausnitzii as the sole known species belonging to the Faecalibacterium genus was observed to have higher abundances post-probiotic treatment, which may mediate host immune function through its butyrogenic effects within the gut microbiome [45]. A growing body of literature has suggested that the production of short chain fatty acids (SCFAs) within the gut possess anti-inflammatory effects, with acetate, propionate, and butyrate being the most abundant products [45, 46]. Mechanistic studies have demonstrated SCFA activation of mammalian G protein-coupled receptors (GPCRs) GPR41 and GPR43 in vitro [47, 48]. Furthermore, studies in mice have suggested that such a mechanism underlies the anti-inflammatory [49] and anti-obesity [50] effects in response to SCFA in the gut; however, there remains a large degree of heterogeneity in relevant findings and further research in this field is warranted [51]. Nonetheless, clinical studies in patients with type-2 diabetes have implicated lower levels of butyrogenic fecal microbiota, including Faecalibacterium, and gut microbiome dysbiosis [52], which may present relevance to individuals with PWS due to its increased prevalence in PWS as a comorbidity. Leptotrichia was also found to be enriched among the salivary microbiota post-probiotic treatment and existing literature has identified the genus as a part of the normal flora of the human oral cavity. In our study, we found that the relative abundance of Leptotrichia is positively correlated with the biosynthesis of N-glycans, neomycin metabolism, and negatively correlated with staphylococcus aureus infection post-BL-11 treatment. As past studies have suggested the importance of glycan expression in the bidirectional microbiota-host and inter-microbiota interactions within the oral microbiome for promoting host oral health and defense [53], these findings may suggest that the increase in Leptotrichia post-BL-11 intervention is a beneficial alteration to individuals with PWS in preventing oral infections from pathogenic species. Similarly, the analysis of predicted functional pathways from the salivary metagenome indicated that salivary Bifidobacterium was found to be significantly positively correlated with vitamin C metabolism and degradation of polycyclic aromatic hydrocarbons (PAH). Vitamin C is an antioxidant and has been suggested to promote host defense against periodontal diseases and promote general tooth and gingivae health [54]. Moreover, the positive correlation between Bifidobacterium abundance and degradation of PAH may suggest a role of Bifidobacterium in the oral metabolism and clearance of PAH. PAH have been characterized as pervasive environmental and dietary toxicants and carcinogens [55]. Existing literature has suggested that the toxicity of PAH is associated with its estrogenicity within the human colon following biotransformation of unabsorbed PAH due to colonic microbiota [56]. Given the findings within the current study, the positive correlation between PAH degradation and Bifidobacterium relative abundance observed in oral saliva samples is suggestive of the potential for BL-11 supplementation to decrease the levels of unabsorbed PAH reaching the colon, thereby reducing the likelihood of PAH-associated toxicity in subjects receiving the BL-11 probiotic. Thus, such findings represent post-probiotic treatment signatures of compositional alterations in the oral microbiota of individuals with PWS that present relevance to enhance host anti-inflammatory responses, contribute to interactions between microbiota, improve host immune defense against pathogenic microbes, and facilitate toxin degradation, though the causal relationship for such microbial functions remains to be validated in future studies.
Taken together, we find that oral BL-11 supplementation can induce specific favorable compositional changes in the salivary microbiota of individuals with PWS following a 12-week interventional period. We further propose that these specific salivary microbiota signatures may represent valuable features in the evaluation of probiotic treatment response as well as the early diagnosis of stunted anthropometric growth, social behavior deficits, and presence of comorbid ASD features in children with PWS. Additionally, due to the non-invasive nature of the sample collection, salivary microbiota sampling is likely preferred over fecal microbiota sampling, provided that the application of such a technique can demonstrate sufficient sensitivity and specificity in classification through future studies. However, due to the number of dropouts, small sample size due to limited saliva sample collection, and a homogenously Chinese study population, the results from the present study should be interpreted with caution and the generalizability of our findings should be carefully evaluated. We hope that the findings of this study could shed light on the complex interactions between the salivary microbiome and the effects of the probiotic strain, as well as changes in aberrant behaviors and associated autism symptoms observed in individuals with PWS in response to probiotic supplementation. Furthermore, given the observed influences on the salivary microbiota following oral supplementation of the BL-11 probiotic in a powder format, it is of interest to assess the potential for further research and development of novel routes of administration for oral-use probiotics.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12602-022-09938-0.

Acknowledgements We sincerely thank Dr. Yiqing Song for his valuable comments on the post hoc analysis. We would also like to thank all the co-authors of our previous clinical trial publication for their contribution to the primary clinical trial. We highly appreciate Dr. Gang Fu, Dr. Qing Song, Dr. Peter Huke, Dr. Yuanyuan Liang, and Dr. Hui Tan from the Baheal Pharmaceutical Group for their generous laboratory support. We thank Dr. Heng Yang from Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences and Ms. Yanan Wang from Suzhou Func Biotech Inc for their assistance in conducting the 16S rRNA Gene Amplicon Sequencing. Lastly, we highly appreciate Dr. Yunfeng Duan and the Beijing Huayuan Academy of Biotechnology for the generous, free supply of the BL-11 probiotic and control.

Author Contribution Conceptualization, X.-J.K.; methodology, X.-J.K.; software, K.L.; validation, K.L.; formal analysis, K.L.; investigation, X.-J.K., K.L.; resources, X.-J.K.; data curation, K.L.; writing—original draft preparation, K.L.; writing—review and editing, K.L., X.-J.K.; visualization, K.L.; supervision, X.-J.K.; project administration, X.-J.K.; funding acquisition, X.-J.K. All authors have read and agreed to the published version of the manuscript.

Funding This research was funded by Massachusetts General Hospital, grant numbers #230361 and #233263.

Data Availability Statement The data presented in this study are openly available in the Sequence Read Archive (SRA) database of The National Center for Biotechnology Information at https://www.ncbi.nlm.nih.gov/bioproject/643297, with accession number PRJNA643297.

Declarations

Ethics Approval The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Second Affiliated Hospital of Kunming Medical University (Review-YJ-2016–06, February 21, 2019).

Consent to Participate Informed consent was obtained from all subjects involved in the study.

Conflict of Interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cassidy SB, ForSYthe M, Heeger S et al (1997) Comparison of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am J Med Genet 68:433–440. https://doi.org/10.1002/(SICI)1096-8628(19970211)68:4<343::AID-AJMG12>3.0.CO;2-4
2. Butler MG, Hartin SN, Hossain WA et al (2018) Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study. J Med Genet 56:149–153. https://doi.org/10.1136/jmedgenet-2018-105301
3. Salehi P, Herzig L, Capone G et al (2018) Comparison of Aberrant Behavior Checklist profiles across Prader-Willi syndrome, Down syndrome, and autism spectrum disorder. Am J Med Genet A 176:2751–2759. https://doi.org/10.1002/ajmg.a.40665
4. Kong X, Zhu J, Tian R et al (2020) Early screening and risk factors of autism spectrum disorder in a large cohort of Chinese patients with Prader-Willi syndrome. Front Psychiatry 11:59434. https://doi.org/10.3389/fpsyg.2020.59434
5. Peng Y, Tan Q, Afhami S et al (2020) The gut microbiota profile in children with Prader-Willi syndrome. Genes-basel 11:904. https://doi.org/10.3390/genes11080904
6. Olsson LM, Poitsou C, Tremaroli V et al (2020) Gut microbiota of obese subjects with Prader-Willi syndrome is linked to metabolic health. Gut 69:1229–1238. https://doi.org/10.1136/gutjnl-2019-319322
7. Qiao Y, Wu M, Feng Y et al (2018) Alterations of oral microbiota distinguish children with autism spectrum disorders from healthy controls. Sci Rep-uk 8:1597. https://doi.org/10.1038/s41598-018-19982-y
8. Hicks SD, Uhlig R, Afshari P et al (2018) Oral microbiome activity in children with autism spectrum disorder. Autism Res 11:1286–1299. https://doi.org/10.1002/aur.1972

9. Ke X, Walker A, Haange S-B et al (2019) Symbiotic-driven improvement of metabolic disturbances is associated with changes in the gut microbiome in diet-induced obese mice. Mol Metab 22:96–109. https://doi.org/10.1016/j.molmet.2019.01.012

10. Hibberd AA, Yde CC, Ziegler ML et al (2019) Probiotic or symbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Benef Microbes 10:121–135. https://doi.org/10.3920/bm2018.0028

11. Kong X-J, Liu K, Zhuang P et al (2021) The effects of Lactobacillus reuteri LR-99 supplementation on body mass index, social communication, fine motor function, and gut microbiome composition in individuals with Prader-Willi syndrome: a randomized double-blind placebo-controlled trial. Probiotics Antimicro 1–13. https://doi.org/10.1007/s12602-021-09800-9

12. Kong X-J, Wan G, Tian R et al (2021) The effects of probiotic supplementation on anthropometric growth and gut microbiota composition in patients with Prader-Willi syndrome: a randomized double-blind placebo-controlled trial. Front Nutr 8:587974. https://doi.org/10.3389/fnut.2021.587974

13. Kong X, Liu J, Cetinbas M et al (2019) New and preliminary evidence on altered oral and gut microbiota in individuals with autism spectrum disorder (ASD): implications for ASD diagnosis and subtyping based on microbial biomarkers. Nutrients 11:2128. https://doi.org/10.3390/nu11092128

14. Xiao J, Fiscella KA, Gill SR (2020) Oral microbiome: possible harbinger for children’s health. Int J Oral Sci 12:12. https://doi.org/10.1038/s41368-020-0082-x

15. Bantim YCV, Kussaba ST, de Carvalho GP et al (2019) Oral health in patients with Prader-Willi syndrome: current perspectives. Clin Cosmet Investigational Dent 11:163–170. https://doi.org/10.2147/cidc.v183981

16. Olsen I, Yamazaki K (2019) Can oral bacteria affect the microbiome of the gut? J Oral Microbiol 11:1586422. https://doi.org/10.1080/20022297.2019.1586422

17. Fung TC (2020) The microbiota-immune axis as a central mediator of gut-brain communication. Neurobiol Dis 136:104714. https://doi.org/10.1016/j.nbd.2019.104714

18. Galland L (2014) The gut microbiome and the brain. J Med Food 17:1261–1272. https://doi.org/10.1089/jmf.2014.7000

19. Gilliam JE (2014) Gilliam Autism Rating Scale-Third Edition. Austin, TX: PRO-ED

20. McIver LJ, Abu-Ali G, Franzosa EA et al (2017) BioBakery: a meta’omic analysis environment. Bioinform Oxf Engl 34:1235–1237. https://doi.org/10.1093/bioinformatics/btx754

21. Rognes T, Flouri T, Nichols B et al (2016) VSEARCH: a versatile open source tool for metagenomics. PeerJ 4:e2584. https://doi.org/10.7717/peerj.2584

22. Price MN, Dehal PS, Arkin AP (2009) FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 26:1641–1650. https://doi.org/10.1093/molbev/msp077

23. Sievers F, Wilm A, Dineen D et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. https://doi.org/10.1038/msb.2011.75

24. DeSantis TZ, Hugenholtz P, Larsen N et al (2006) Greengenes, a chimera-checked 16S RNA gene database and workbench compatible with ARB. Appl Environ Microb 72:5069–5072. https://doi.org/10.1128/aem.03006-05

25. McMurdie PJ, Holmes S (2013) phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8:e61217. https://doi.org/10.1371/journal.pone.0061217

26. Nappal S, Singh R, Yadav D, Mande SS (2020) MetagenoNets: comprehensive inference and meta-insights for microbial correlation networks. Nucleic Acids Res 48:W572–W579. https://doi. org/10.1093/nar/gkaa254

27. Segata N, Izard J, Waldron L et al (2011) Metagenomic biomarker discovery and explanation. Genome Biol 12:R60. https://doi.org/10.1186/gb-2011-12-6-r60

28. Mallick H, Rahnavard A, McIver LJ et al (2021) Multivariable association discovery in population-scale meta-omics studies. Bioxiv. https://doi.org/10.1101/2021.01.20.427420

29. Narengaowa KW, Lan F et al (2021) The oral-gut-brain AXIS: the influence of microbes in Alzheimer’s disease. Front Cell Neurosci 15:633735. https://doi.org/10.3389/fncel.2021.633735

30. Aiyé SE, Dinan TG, Cryan JF (2014) Immune modulation of the brain-gut-microbe axis. Front Microbiol 5:146. https://doi.org/10.3389/fmicb.2014.00146

31. Jensen EA, Young JA, Jackson Z et al (2020) Growth hormone deficiency and excess alter the gut microbiome in adult male mice. Endocrinology. https://doi.org/10.1210/endo/bqaa026

32. You M, Mo S, Leung WK, Watt RM (2013) Comparative analysis of oral treponemes associated with periodontal health and disease. Bmc Infect Dis 13:174. https://doi.org/10.1186/1471-2334-13-174

33. Zhu B, Macleod LC, Newsome E et al (2019) Aggregatibacter actinomycetemcomitans mediates protection of Porphyromonas gingivalis from Streptococcus sanguinis hydrogen peroxide production in multi-species biofilms. Sci Rep-uk 9:4944. https://doi.org/10.1038/s41598-019-41667-9

34. Vonaesch P, Morien E, Andriannimiaida L et al (2018) Stunted childhood growth is associated with decompartmentalization of the gastrointestinal tract and overgrowth of oropharyngeal taxa. Proc National Acad Sci 115:201806573. https://doi.org/10.1073/pnas.1806573115

35. Münger E, Montiel-Castro AJ, Langhans W, Pacheco-López G (2018) Reciprocal interactions between gut microbiota and host social behavior. Front Integr Neurosci 12:21. https://doi.org/10.3389/fnint.2018.00021

36. Wu W-L, Adame MD, Liou C-W et al (2021) Microbiota regulate social behaviour via stress response neurons in the brain. Nature 595:409–414. https://doi.org/10.1038/s41586-021-03669-y

37. Agranony O, Meninger-Mordechay S, Uzan A et al (2021) Gut microbiota determines the social behavior of mice and induces metabolic and inflammatory changes in their adipose tissue. Npj Biofilms Microbiomes 7:28. https://doi.org/10.1038/s41522-021-00193-9

38. Maitre Y, Micheneau P, Delpierre A et al (2020) Did the brain and oral microbiota talk to each other? A review of the literature. J Clin Medicine 9:3876. https://doi.org/10.3390/jcm91123876

39. Chaudhari DS, Dhotre DP, Agarwal DM et al (2020) Gut, oral and skin microbiome of Indian patrilineal families reveal perceptible association with age. Sci Rep-uk 10:5685. https://doi.org/10.1038/s41598-020-62195-5

40. Varian BJ, Poutahidis T, DiBenedictis BT et al (2017) Microbial lysate upregulates host oxytocin. Brain Behav Immun 61:36–49. https://doi.org/10.1016/j.bbi.2016.11.002

41. Erdman SE, Poutahidis T (2016) Chapter five microbes and oxytocin benefits for host physiology and behavior. Int Rev Neurobiol 131:91–126. https://doi.org/10.1016/bs.irn.2016.07.004

42. Carter CS, Kenkel WM, MacLean EL et al (2020) Is oxytocin “nature’s medicine”? Pharmacol Rev 72:829–861. https://doi.org/10.1124/pr.120.019398

43. Acheson KJ, Zahorska-Markiewicz B, Pittet P et al (1980) Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. Am J Clin Nutrition 33:989–997. https://doi.org/10.1093/ajcn/33.5.989

44. Tabrizi R, Saneei P, Lankarani KB et al (2018) The effects of caffeine intake on weight loss: a systematic review and dos-response
meta-analysis of randomized controlled trials. Crit Rev Food Sci
59:1–9. https://doi.org/10.1080/10408398.2018.1507996
45. Cao X, Liu K, Liu J et al (2021) Dysbiotic gut microbiota and
dysregulation of cytokine profile in children and teens with autism
spectrum disorder. Front Neurosci-switz 15:635925. https://doi.
org/10.3389/fnins.2021.635925
46. Cummings JH, Pomare EW, Branch WJ et al (1987) Short chain
fatty acids in human large intestine, portal, hepatic and venous
blood. Gut 28:1221. https://doi.org/10.1136/gut.28.10.1221
47. Poul EL, Loison C, Struyf S et al (2003) Functional characterization
of human receptors for short chain fatty acids and their role
in polymorphonuclear cell activation*. J Biol Chem 278:25481–
25489. https://doi.org/10.1074/jbc.m301403200
48. Brown AJ, Goldsworthy SM, Barnes AA et al (2003) The orphan
G protein-coupled receptors GPR41 and GPR43 are activated by
propionate and other short chain carboxylic acids*. J Biol Chem
278:11312–11319. https://doi.org/10.1074/jbc.m211609200
49. Macia L, Tan J, Vieira AT et al (2015) Metabolite-sensing recep-
tors GPR43 and GPR109A facilitate dietary fibre-induced gut
homeostasis through regulation of the inflammasome. Nat Commun
6:6734. https://doi.org/10.1038/ncomms7734
50. Lu Y, Fan C, Li P et al (2016) Short chain fatty acids prevent high-
fat-diet-induced obesity in mice by regulating G protein-coupled
receptors and gut microbiota. Sci Rep-uk 6:37589. https://doi.org/
10.1038/srep37589
51. Ang Z, Ding JL (2016) GPR41 and GPR43 in obesity and inflam-
mation – protective or causative? Front Immunol 7:28. https://doi.
org/10.3389/fimmu.2016.00028
52. Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association
study of gut microbiota in type 2 diabetes. Nature 490:55–60.
https://doi.org/10.1038/nature11450
53. Cross BW, Ruhl S (2018) Glycan recognition at the saliva – oral
microbiome interface. Cell Immunol 333:19–33. https://doi.org/
10.1016/j.cellimm.2018.08.008
54. Rubinoff AB, Latner PA, Pasut LA (1989) Vitamin C and oral
health. J Can Dent Assoc 55:705–707
55. Ramesh A, Walker SA, Hood DB et al (2004) Bioavailabil-
ity and risk assessment of orally ingested polycyclic aromatic
hydrocarbons. Int J Toxicol 23:301–333. https://doi.org/10.
1080/10915810490517063
56. de Wiele TV, Vanhaecke L, Boeckaert C et al (2005) Human colon
microbiota transform polycyclic aromatic hydrocarbons to estro-
genic metabolites. Environ Health Persp 113:6–10. https://doi.org/
10.1289/ehp.7259

Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.